Skip to content

PHARMALABEL

Absorbed by SL CORPORATE on 01-09-2021 KBO/BCE: BE 0429.143.044

Last board

1 office holder, no change since 2020
Managing director
appointed by deed of 25-11-2020
also on the board of 2 other companies
Signing authorityThe articles say who may bind the company, for example by signing a contract.
Each director alone
deed of 14-05-2021

Office holders in the KBO →

Mandates through the years

1 name, the dashed line is today

Managing director
LeadershipEarlierend not dated
Mandates as a list
    • Manager (not named in the articles), appointed by deed of 30-11-2018, last mentioned in 2018
    • Managing director, appointed by deed of 25-11-2020, still in office
With Starter you also see 3 former office holders in the mandate history. See the plans →

Control

PHARMALABEL was absorbed by on 06-05-2021.

Capital

Capital
€1,621,814.63
Shares
4,034
Contribution per share
€402
Equity per share
€650 in 2020
Source
2019 annual accounts

Owners through the years

as the annual accounts name them
100%
Owners as a list
    • 2018 to 2020: 100%

Source: lists of holdings in the owners' accounts

Articles of association

deed of 02-07-2019 (in Dutch)
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
Board ruleThese rules set how the board is made up, meets and takes decisions.
At least 1 director
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
Third Friday of June at 11:00

Shareholders

Stated in the deed deed of 01-09-2021 ↗
  • all shares
After 2 capital increases deed of 02-07-2019 ↗
  • 884 shares · €1,600,000 · schuldvordering

Capital transactions

Capital over time
  1. 14-05-2021 Capital stated in the deed · 4,034 shares
  2. 02-07-2019 Capital increase of €5,569.20 · to €25,400.68 · 884 new shares · in kind
  3. 02-07-2019 Capital increase of €1,594,430.80 · to €1,619,831.48 · no new shares · inlijving onbeschikbare rekening uitgiftepremies
  4. 02-07-2019 Converted to unavailable equity · €1,619,831.48
  5. 02-07-2019 Converted to available equity

Next steps